AnaBios Boosts Discovery of Safer, More Effective Medicines With License From the University of Louisville
14 févr. 2023 09h00 HE | AnaBios
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new drugs, today announced a technology transfer...
AnaBios Announces Inaugural Translational Research Conference to Be Held in San Diego
08 nov. 2022 09h00 HE | AnaBios
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AnaBios today announced the inaugural Translational Research Conference to be held Feb. 27-28, 2023, in San Diego, California. The conference will gather...
AnaBios Further Expands Business Development Team With Hiring of Dr. Blake Anson
14 juin 2022 09h00 HE | AnaBios
SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- AnaBios is pleased to announce the hire of Blake Anson, Ph.D., as Vice President of Business Development. In this new role, Dr. Anson will contribute to...
AnaBios Closes Financing With Ampersand Capital Partners
07 juin 2022 09h00 HE | AnaBios
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- AnaBios Corporation, a leading preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to...
AnaBios Introduces High-Quality Human Primary Liver Cells for Preclinical Drug Discovery
24 mars 2022 08h00 HE | AnaBios
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Today, AnaBios announced it will start providing high-quality human primary liver cells to pharmaceutical, biotech and academic laboratories to further...
NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States
30 sept. 2021 11h00 HE | AnaBios
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409...